Apimeds Pharmaceuticals US Inc
APUS | AMEX
$2.88
-$0.33 (-10.28%)
At close: Oct 30, 2026, 3:59 PM ET
$3.14
+$0.26 (+9.03%)
Pre-market:
Nov 2, 2026, 6:10 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 5.71K | n/a | n/a | n/a | n/a |
Gross Profit | -5.71K | n/a | n/a | n/a | n/a |
Operating Income | -11.91M | -1.28M | -747.44K | -639.53K | -1.02M |
Interest Income | 107.6K | 2.82K | 7.81K | n/a | n/a |
Pretax Income | -6M | -1.39M | -777.69K | -668.67K | -1.03M |
Net Income | -6M | -1.39M | -777.69K | -668.67K | -1.03M |
Selling & General & Admin | 10.27M | 1.28M | 648.89K | 271.53K | 529.56K |
Research & Development | 1.63M | n/a | 98.54K | 368K | 489.94K |
Other Expenses | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 11.91M | 1.28M | 747.44K | 639.53K | 1.02M |
Interest Expense | 283.01K | 117.72K | 38.07K | 29.14K | 6.74K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 11.91M | 1.28M | 747.44K | 639.53K | 1.02M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 1.09M | 115.27K | 115.27K | 115.27K | 115.27K |
Shares Outstanding (Diluted) | 1.09M | 126.93K | 126.93K | 126.93K | 126.93K |
EPS (Basic) | -5.50 | -12 | -6.75 | -5.80 | -8.90 |
EPS (Diluted) | -5.50 | -11 | -6.13 | -5.27 | -8.08 |
EBITDA | -5.71M | -1.27M | -739.63K | -639.53K | -1.02M |
EBIT | -5.72M | -1.27M | -739.63K | -639.53K | -1.02M |
Depreciation & Amortization | 5.71K | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove APUS